| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.23 | 6e-06 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.21 | 5e-05 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0009 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.093 | 0.004 |
| mRNA | Bryostatin 1 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.094 | 0.007 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | 0.095 | 0.01 |